Assembly Biosciences Inc (ASMB) Q2 2016 10-Q Quarterly Earnings

Short answer

Assembly Biosciences Inc (ASMB) filed its Q2 2016 10-Q quarterly report on Aug 9, 2016 for the quarter ended Jun 30, 2016.

AI summary of MD&A and risk factor updates

No product revenue, reflecting no FDA-approved products and continued operating losses
R&D expense $7.6M, up from $4.6M YoY, with HBV-cure research increasing $2.2M
Net loss $21.1M, including $3.0M stock-based compensation expense
Operating cash use $16.0M vs $8.1M YoY, with no financing cash flow
Cash, equivalents and marketable securities expected to fund operations at least twelve months, additional capital needed thereafter

No material changes identified from the prior 10-K; risks appear carried forward
Liquidity: current resources expected to fund operations into fourth quarter of 2017
Financial: accumulated deficit reached $185.1 million as of June 30, 2016
Regulatory: FDA approval requires extensive preclinical and clinical data, with potential for additional testing or approval limits
Operational: HBV and microbiome candidates remain preclinical, with no approved products or product revenue
Intellectual property: no issued patents currently cover product candidates or technologies

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.